Market Research Report
Global BCL-2 (B-cell lymphoma 2) Inhibitors Market 2019-2023
|Published by||TechNavio (Infiniti Research Ltd.)||Product code||905966|
|Published||Content info||111 Pages
Delivery time: 1-2 business days
|Global BCL-2 (B-cell lymphoma 2) Inhibitors Market 2019-2023|
|Published: August 2, 2019||Content info: 111 Pages||
BCL-2 inhibitors are used as a targeted therapy to treat cancer by blocking the BCL-2 protein. Technavio's BCL-2 inhibitors market analysis considers sales from the combination therapy and monotherapy segments. Our analysis also considers the sales of BCL-2 inhibitors in Asia, Europe, North America, and ROW. In 2018, the combination therapy segment held the highest market share, which is expected to remain prevalent over the forecast period. Factors such as label expansion of venetoclax from monotherapy to combination therapy and high efficacy and tolerability of combination therapy compared with monotherapy will significantly help the market segment in maintaining its leading position. Also, our global BCL-2 inhibitors report has observed market growth factors such as rise in geriatric population, growing awareness about hematological malignancies, and high target affinity and specificity of BCL-2 inhibitors. However, the availability of substitutes, adverse effects of BCL-2 inhibitors, and drug resistance may hamper the growth of the BCL-2 inhibitors industry over the forecast period.
Most of the times, symptoms of hematological malignancies are mild or not apparent. This may hamper the market growth as the patient may not know how to identify symptoms and opt to visit a specialist. To combat this challenge, many organizations and market vendors have been organizing awareness programs to educate patients about indication symptoms and available diagnostic methods and treatment options. These awareness programs also conduct cancer screening. As a result, appropriate diagnosis and treatment will take place. This will increase sales of BCL-2 inhibitors, which will lead to the expansion of the BCL-2 inhibitors market at a CAGR of almost 39% during 2019-2023.
The only approved therapy available in the market to treat hematological malignancies is venetoclax, which has limited anti-BCL activity. Therefore, vendors have started formulating novel drugs that can be administered in combination with other therapies. These novel drugs are formulated to overcome drug resistance caused by BCL-2 inhibitors and provide enhanced efficacy. As a result, this trend will have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global BCL-2 (B-cell lymphoma 2) inhibitors market during the forecast period 2019-2023, view our report.
With the presence of a few major players, the global BCL-2 inhibitors market is concentrated. Technavio's robust vendor analysis is designed to help clients in improving their market positions, and in line with this, this report provides a detailed analysis of several leading BCL-2 inhibitors manufacturers, which include AbbVie Inc. and F. Hoffmann-La Roche Ltd.
Also, the BCL-2 inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Key leading countries